Harmony Biosciences is projected to report Q2 2026 revenue of $249.0 million and EPS of $0.97, with the stock’s current price of $35.24 trading well below the average analyst target of $45.40.
The primary story for investors is the performance of WAKIX (pitolisant) net product revenue, which management recently pre-announced at a record $261 million for the quarter.
Market focus will also center on the company's progress with its next-generation Pitolisant-GR NDA submission and the search for a permanent CFO following Glenn Reicin's recent departure in July. Despite consistent double-digit revenue growth, sentiment remains cautious as the company seeks to break a streak of missing quarterly EPS estimates.